Previous 10 | Next 10 |
2024-01-04 16:51:37 ET DENVER, Colo., Jan. 4, 2024 ( www.247marketnews.com )- Dermata Therapeutics, Inc. (NASDAQ: DRMA) announced, after today’s market close, that it was issued a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis, entitled “Comp...
- This is the Company's first patent issued for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company is currently discussing partnership opportunities to advance development of DMT410 - - In 2022, the Japanese prevalence of hyperhid...
- About 550 patients will be treated once weekly for 12 weeks - - STAR-1 topline results expected in first quarter of 2025 - - Acne affects about 50 million patients in the U.S. - SAN DIEGO, CA / ACCESSWIRE / December 20, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("Der...
2023-12-18 14:46:47 ET Top 3 Strategies to Use for Trading Penny Stocks Next Year Penny stocks are a popular but risky investment option due to their potential for high returns. Having a trading strategy with penny stocks is important in order to minimize the risk involved and maximize ...
2023-12-08 08:07:30 ET More on Dermata Therapeutics Seeking Alpha’s Quant Rating on Dermata Therapeutics Historical earnings data for Dermata Therapeutics Financial information for Dermata Therapeutics For further details see: Dermata Therapeutics ...
- DMT310 Phase 3 STAR-1 (Spongilla Treatment of Acne Research) clinical trial will evaluate the efficacy and safety of once-weekly treatments of DMT310 for 12 weeks in moderate-to-severe acne patients - - Topline results from STAR-1 clinical trial expected in Q1 2025 - - DMT310, if appr...
2023-11-10 07:49:29 ET More on Dermata Therapeutics Seeking Alpha’s Quant Rating on Dermata Therapeutics Historical earnings data for Dermata Therapeutics Financial information for Dermata Therapeutics For further details see: Dermata Therapeutics ...
- Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 - - Received positive feedback from FDA on its End of Phase 2 meeting package in June 2023 - - Completed start-up activities to support DMT310 Phase 3 STAR-1 clinical trial in acne - SAN...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Dermata Therapeutics Inc. (DRMA) is expected to report for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Company Name:
DRMA Stock Symbol:
NASDAQ Market:
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreement...
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis - SAN...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...